LB Pharmaceuticals shareholders elect directors, ratify auditor
LB Pharmaceuticals Inc. reported the results of its 2026 Annual Meeting of Stockholders.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
LB Pharmaceuticals Inc. reported the results of its 2026 Annual Meeting of Stockholders. Three Class I directors — Robert A. Lenz, M.D., Ph.D., Rebecca Luse, and Ran Nussbaum — were elected to three-year terms ending at the 2029 annual meeting.
Stockholders also ratified the appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with a strong majority of votes cast in favor and minimal opposition or abstentions.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Votes for Lenz: 20,059,577 votes
Votes for Luse: 18,530,680 votes
Votes for Nussbaum: 18,748,511 votes
+5 more
8 metrics
Votes for Lenz
20,059,577 votes
Election of Robert A. Lenz, M.D., Ph.D. as Class I director
Votes for Luse
18,530,680 votes
Election of Rebecca Luse as Class I director
Votes for Nussbaum
18,748,511 votes
Election of Ran Nussbaum as Class I director
Broker non-votes directors
3,216,636 votes
Broker non-votes for each Class I director election
Auditor ratification for votes
23,275,974 votes
Ratification of BDO USA, P.C. as auditor for 2026
Auditor ratification against votes
5,490 votes
Votes against ratifying BDO USA, P.C. as auditor
Auditor ratification abstentions
2,753 votes
Abstentions on ratifying BDO USA, P.C. as auditor
Meeting quorum
Quorum present
2026 Annual Meeting of Stockholders of LB Pharmaceuticals Inc.
Key Terms
Emerging growth company, Broker Non-Votes, independent registered public accounting firm, Annual Meeting of Stockholders, +1 more
5 terms
Emerging growth company regulatory
"Emerging growth company Item 5.07. Submission of Matters to a Vote of Security Holders."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Broker Non-Votes financial
"For | | Withheld | | Broker Non-Votes Robert A. Lenz, M.D., Ph.D."
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026."
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Annual Meeting of Stockholders financial
"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 3, 2026, at which a quorum was present."
Class I directors financial
"elected the three persons listed below as Class I directors, each to serve a three-year term"
Class I directors are the subset of a company’s board whose terms expire at a specific annual meeting under a staggered election system that divides directors into multiple groups with different re-election years. For investors this matters because staggered classes slow how quickly shareholders can replace the board, affecting takeover risk, governance change and the pace of corporate decisions — like rotating only part of a team instead of swapping everyone at once.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did LB Pharmaceuticals Inc. (LBRX) vote on at the 2026 annual meeting?
Stockholders voted on electing three Class I directors and ratifying BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Both proposals received strong support from shares present at the meeting.
Which directors were elected at LB Pharmaceuticals Inc. (LBRX) 2026 annual meeting?
Robert A. Lenz, M.D., Ph.D., Rebecca Luse, and Ran Nussbaum were elected as Class I directors. Each will serve a three-year term until the 2029 Annual Meeting of Stockholders, continuing until a successor is elected or upon earlier death, resignation, or removal.
How many votes did LB Pharmaceuticals Inc. (LBRX) director nominees receive?
Robert A. Lenz received 20,059,577 votes for and 8,004 withheld. Rebecca Luse received 18,530,680 for and 1,536,901 withheld. Ran Nussbaum received 18,748,511 for and 1,319,070 withheld, with 3,216,636 broker non-votes for each nominee.
Was BDO USA, P.C. ratified as LB Pharmaceuticals Inc. (LBRX) auditor for 2026?
Yes. Stockholders ratified BDO USA, P.C. as independent registered public accounting firm for the year ending December 31, 2026, with 23,275,974 votes for, 5,490 against, 2,753 abstentions, and no broker non-votes reported for this proposal.
What are broker non-votes in the LB Pharmaceuticals Inc. (LBRX) director elections?
Broker non-votes are shares held in street name that were not voted on a non-routine matter like director elections. For each director nominee, 3,216,636 broker non-votes were recorded, reflecting shares present but not voted on those specific proposals.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates